graph EGM comparisons
sacituzumab govitecantitleStandard of Care (SoC)titleASCENT (all population), 2021 NCT02574455 mBC-Triple negative (TNBC) - 2nd Line (L2) 267/262ASCENT (patients without brain metastases), 2021 NCT02574455 mBC-Triple negative (TNBC) - 2nd Line (L2) 235/233

Pathology:  mBC-Triple negative (TNBC) - 2nd Line (L2); 

mBC-Triple negative (TNBC) - 2nd Line (L2)
ASCENT (all population), 2021ASCENT (patients without brain metastases), 2021
sacituzumab govitecan2T1T1
Standard of Care (SoC)0T0T0